Morgan Stanley
LEXX icon

Morgan Stanley’s Lexaria Bioscience LEXX Stock Holding History

Morgan Stanley’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
3
– – ﹤0.01% 8261
2025
Q4 		$2 Buy
+3
New +$3 ﹤0.01% 8176
2025
Q1 		– Sell
-20,229
Closed -$42.5K – 8167
2024
Q4 		$42.5K Sell
20,229
-2,753
-12% -$6.78K ﹤0.01% 6341
2024
Q3 		$70.1K Hold
22,982
– – ﹤0.01% 6122
2024
Q2 		$63.9K Sell
22,982
-372
-2% -$1.12K ﹤0.01% 6103
2024
Q1 		$84.8K Buy
+23,354
New +$59.5K ﹤0.01% 6056
2022
Q1 		– Sell
-1
Closed – – 8044
2021
Q4 		$0 Sell
1
-999
-100% -$5.68K ﹤0.01% 8042
2021
Q3 		$6K Buy
+1,000
New +$6.39K ﹤0.01% 7450

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Morgan Stanley's LEXX Position: Q1 2026 in Review

Morgan Stanley held its Lexaria Bioscience (LEXX) position steady in Q1 2026 at 3 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8261.

Morgan Stanley first reported a position in LEXX in Q3 2021 and has held it in 8 quarters since. The position peaked at $84.8K in Q1 2024. 28 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

  • Morgan Stanley held 3 shares of Lexaria Bioscience worth $2 as of Q1 2026.
  • Morgan Stanley left its Lexaria Bioscience share count unchanged in Q1 2026.
  • Lexaria Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8261 holding.
  • Morgan Stanley first reported a position in Lexaria Bioscience in Q3 2021 and has held it in 8 quarters since.
  • Morgan Stanley's Lexaria Bioscience position peaked at $84.8K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.